Inquiry Basket
CAS No.: 1662687-83-3
Cat No.: BADC-01646
4.5 
Mal-PEG2-Val-Cit-PABA is a maleimide-activated protease-sensitive ADC linker supporting precise payload release in lysosomal environments, optimizing antibody-drug conjugate efficacy.
Structure of 1662687-83-3
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
Mal-PEG2-Val-Cit-PABA is a specialized ADC linker widely used in the design and construction of antibody-drug conjugates (ADCs) and targeted bioconjugation applications. Featuring a maleimide (Mal) group, a PEG2 spacer, and a Val-Cit-PABA cleavable linker, it enables efficient and site-specific conjugation with cysteine residues on monoclonal antibodies. The PEG2 spacer improves hydrophilicity and reduces steric hindrance, while the Val-Cit-PABA sequence allows controlled intracellular cleavage and payload release. In ADC linker design, Mal-PEG2-Val-Cit-PABA supports modular linker construction and preserves antibody integrity for precise delivery of cytotoxic payloads.
In payload conjugation applications, Mal-PEG2-Val-Cit-PABA is compatible with various ADC cytotoxins, including microtubule inhibitors and DNA-targeting agents. The maleimide group reacts efficiently with thiol groups on antibodies, ensuring reproducible and site-specific attachment of ADC payloads. The PEG2 spacer enhances solubility and flexibility, while the Val-Cit-PABA cleavable sequence enables selective release of cytotoxins within lysosomal compartments of target tumor cells. Researchers can leverage this linker to optimize ADC stability, payload release kinetics, and overall therapeutic performance for both preclinical studies and industrial-scale ADC production.
From an application perspective, Mal-PEG2-Val-Cit-PABA is extensively applied in oncology-focused ADC research, targeted drug delivery systems, and protein bioconjugation studies. Its combination of maleimide chemistry, PEG2 flexibility, and Val-Cit-PABA cleavable linker allows efficient, site-specific, and controlled conjugation while maintaining antibody structure and function. By integrating Mal-PEG2-Val-Cit-PABA into ADC linker design, developers can construct stable, flexible, and highly soluble linker-payload conjugates that enable tumor-specific delivery, optimized pharmacokinetics, and enhanced therapeutic efficacy in modern ADC development.
| Catalog | Product Name | CAS | Inquiry |
|---|---|---|---|
| BADC-01679 | Mal-PEG2-Val-Cit-PABA-PNP | 1345681-52-8 | |
| BADC-00697 | Boc-Val-Cit-PABA | 870487-09-5 |
What is Mal-PEG2-Val-Cit-PABA used for in ADC development?
Mal-PEG2-Val-Cit-PABA is a cleavable linker in ADCs, connecting cytotoxic payloads to antibodies. It remains stable in circulation but allows controlled payload release in target cells via enzymatic cleavage, ensuring precise therapeutic delivery.
4/9/2020
Could you explain how the Val-Cit-PABA motif functions in Mal-PEG2-Val-Cit-PABA?
The Val-Cit-PABA motif is cathepsin-cleavable. In lysosomes, cathepsin enzymes cleave the Val-Cit bond, releasing the payload, enhancing ADC specificity and minimizing off-target toxicity.
11/9/2021
We are interested in what is the role of the PEG2 spacer in Mal-PEG2-Val-Cit-PABA.
PEG2 increases solubility and reduces ADC aggregation. It provides flexibility between the antibody and payload, improving pharmacokinetics and stability while minimizing steric interference with antigen binding.
14/3/2019
Good morning! What types of payloads are compatible with Mal-PEG2-Val-Cit-PABA?
Mal-PEG2-Val-Cit-PABA is compatible with thiol-containing cytotoxic payloads like auristatins and maytansinoids. The maleimide reacts with thiols to form stable conjugates, allowing reproducible ADC construction.
6/6/2022
Good morning! What are the recommended storage conditions and handling instructions for Mal-PEG2-Val-Cit-PABA?
Mal-PEG2-Val-Cit-PABA should be stored at -20°C in a dry, inert atmosphere to maintain stability. Avoid repeated freeze-thaw cycles and prolonged exposure to moisture. Aliquoting is recommended for repeated use to preserve maleimide reactivity, ensuring consistent performance in antibody-drug conjugation experiments.
15/7/2019
— Dr. Emily Carter, Senior Scientist (USA)
Mal-PEG2-Val-Cit-PABA linker enabled precise conjugation with minimal side reactions, greatly improving our ADC development efficiency.
14/3/2019
— Prof. David Müller, Medicinal Chemist (Germany)
The stability and solubility of Mal-PEG2-Val-Cit-PABA allowed smooth batch synthesis. Excellent quality.
15/7/2019
— Dr. Anna Rossi, Bioconjugation Specialist (Italy)
BOC Sciences delivered Mal-PEG2-Val-Cit-PABA on schedule. Reproducibility across batches was impressive.
6/6/2022
— Mr. James Thompson, R&D Manager (UK)
Using Mal-PEG2-Val-Cit-PABA, we achieved consistent payload release under intracellular conditions.
4/9/2020
— Dr. Laura Jensen, ADC Project Lead (Denmark)
Excellent technical support and documentation accompanied Mal-PEG2-Val-Cit-PABA. Highly recommended.
— Ms. Sophie Martin, Senior Researcher (France)
Mal-PEG2-Val-Cit-PABA significantly facilitated our high-throughput ADC screening. Product quality was outstanding.
11/9/2021
Mal-PEG2-Val-Cit-PABA
Required fields are marked with *
Mal-PEG2-Val-Cit-PABA
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
